Alzheimer’s Disease: Dynamic Market Forecast to 2026
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Alzheimer’s Disease (AD) is a rapidly evolving field in which new developments are constantly influencing the market landscape.
The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the AD space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the projected market forecast.
Scope
The Dynamic Market Forecast consists of a slide deck detailing key market-impacting events that have occurred since the last publication of the AD report, along with an updated Excel-based forecasting model which reflects the projected influence of these events on the future AD market.
The Key Events covered in this AD Dynamic Market Forecast include:
• Potential first humanized monoclonal antibody for the treatment of AD could enter in the market in 2021
• Approval and launch of DMT classes will revolutionize the field of AD therapeutics, regardless of their cost and increase competition
• Three of BACE1 inhibitors have been terminated since September 2017 so elenbecestat is now leading this class due to recently published positive data results
• Combination of treatment with CNP520 and CAD106 from Novartis could open new option for the treatment of AD
• Launch of new four pipeline drugs added in the late stage pipeline
Components of the slide deck include:
• Timeline of market-impacting events
• Key clinical trial landscape updates
• Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
• Overview of updates to the forecast model based on anticipated future impact of events
• Forward-looking events calendar listing expected key updates to the AD competitive space through October2018-October 2021
Other events included in the analysis include:
• Regulatory filings
• Approval decisions
• Pricing changes
• Patent litigation
• Clinical trial data announcements
• Clinical trial failures
• Clinical trial timeline updates
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global AD market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Biogen
Grifols
Novartis
Eisai
AZTherapies
Merck
AstraZeneca
Jannsen
Axovant
Otsuka
Intra-Cellular Therapies
TauRx Pharmaceuticals
Takeda
Archer Pharmaceuticals
Axsome Therapeutics
Avanir Pharmaceuticals
AB Science
Accera
Shire
Neurimmune
Amgen
Genentech
Lundbeck
MorphoSys
Eli Lilly
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.